US · TRAW
Traws Pharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Newtown, PA 18940
- Website
- trawspharma.com
Price · as of 2024-12-31
$1.49
Market cap 7.87M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $21.71 | +1,357.05% |
| Intrinsic Value(DCF) | $399.35 | +26,702.01% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $430,875.00 | $261,549,226.80 | $122,173.26 | $0.00 | $26,781,548.38 |
| 2014 | $126,562.50 | $50,625.00 | $0.00 | $0.00 | $11,820,227.70 |
| 2015 | $25,312.50 | $1,001,419.35 | $388,780,461.81 | $0.00 | $0.00 |
| 2016 | $15,468.75 | $581,789.36 | $16,186.76 | $0.00 | $1,030,288.03 |
| 2017 | $6,018.75 | $6,593.24 | $0.00 | $0.00 | $1,113,338.46 |
| 2018 | $1,327.50 | $846.80 | $0.00 | $0.00 | $0.00 |
| 2019 | $172.50 | $311.99 | $21,043.85 | $0.00 | $0.00 |
| 2020 | $416.25 | $166.50 | $0.00 | $0.00 | $4,194.65 |
| 2021 | $40.00 | $136.96 | $47.44 | $0.00 | $0.00 |
| 2022 | $19.00 | $83.52 | $14.68 | $0.00 | $0.00 |
| 2023 | $24.00 | $9.60 | $0.00 | $0.00 | $0.00 |
| 2024 | $2.83 | $21.71 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Traws Pharma, Inc.'s (TRAW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $21.71
- Current price
- $1.49
- AI upside
- +1,357.05%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$399.35
+26,702.01% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TRAW | Traws Pharma, Inc. | $1.49 | 7.87M | +1,357% | +26,702% | — | — | -0.08 | -0.14 | 19.44 | 0.10 | -0.14 | -0.14 | 94.69% | -21835.40% | -24192.04% | 521.75% | 156.37% | -229.51% | 0.00 | — | 2.16 | 2.00 | 0.13 | 5601.00% | 0.00% | 6601.00% | -678.00% | -2.58 | 94.40% | 0.00% | 0.00% | 11.77% | 0.34 | 0.57 | -74.97 | -42.23 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| BRTX | BioRestorative Therapies,… | $0.23 | 2.03M | +18,797% | +1,222% | — | — | -1.34 | 1.41 | 30.01 | -0.11 | — | 1.52 | 93.00% | -2881.59% | -2239.25% | -96.89% | 745.38% | -72.15% | 0.00 | — | 2.97 | 2.91 | 0.05 | -5304.00% | 17503.00% | 2629.00% | -69.27% | -2.20 | 537.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 3.25 | -18.17 |
| CING | Cingulate Inc. | $6.27 | 35.15M | — | — | — | — | -0.95 | 1.97 | — | -0.51 | — | 1.97 | 0.00% | — | — | -5305.02% | 1019.77% | -169.38% | 0.68 | — | 2.55 | 2.46 | 0.48 | -9673.00% | — | 2231.00% | -126.84% | -3.71 | 1216.50% | 0.00% | 0.00% | 71.84% | -0.49 | -0.41 | — | -11.88 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMNN | Imunon, Inc. | $3.25 | 8.19M | — | — | — | — | -0.56 | 2.47 | — | -0.32 | — | 2.47 | 0.00% | — | — | -211.21% | 3263.61% | -117.72% | 0.27 | — | 1.67 | 1.23 | 0.26 | -2500.00% | — | -303.00% | -180.33% | -3.94 | 3221.31% | 0.00% | 0.00% | 4.96% | -0.30 | -0.30 | — | -63.56 |
| IMRN | Immuron Limited | $0.77 | 4.96M | +2,352% | +18,330% | — | — | -3.14 | 2.04 | 2.25 | -2.00 | — | 2.04 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -2623.00% | 4863.00% | 436.00% | -37.47% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.99 | -1.73 | 1.46 | -6.75 |
| MBIO | Mustang Bio, Inc. | $1.01 | 7.37M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| SNSE | Sensei Biotherapeutics, I… | $30.50 | 38.48M | — | — | — | — | -7.50 | 5.89 | — | -6.39 | — | 5.89 | 0.00% | — | — | -58.40% | -1014.51% | -50.37% | 0.10 | -351.81 | 7.70 | 7.59 | 0.21 | -164.00% | — | -2294.00% | -10.98% | -4.53 | -795.13% | 0.00% | 0.00% | 0.00% | -5.96 | -7.60 | — | 10.02 |
About Traws Pharma, Inc.
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- CEO
- Iain D. Dukes
- Employees
- 6
- Beta
- 1.67
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($399.35 ÷ $1.49) − 1 = +26,702.01% (DCF, example).